The 3 analysts offering 12-month price forecasts for Progenics Pharmaceuticals Inc have a median target of 7.00, with a high estimate of 14.00 and a low estimate of 6.50. The median estimate represents a +39.72% increase from the last price of 5.01.
The current consensus among 3 polled investment analysts is to Buy stock in Progenics Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.26
Reporting Date Mar 05
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.